Water Tower Hour Recap
We hosted Jaguar Health’s CEO Lisa Conte on The Water Tower Hour podcast yesterday. She discussed the company’s origins, its current product, and its pipeline. Conte founded Jaguar upon her return from a trip climbing Mount Kilimanjaro, where she discovered a plant-based substance that helped to relieve altitude sickness. She then founded Jaguar, which pioneered plant-based therapies to treat severe diarrhea in several subgroups of patients. Jaguar’s current product, Mytesi® (crofelemer), is currently on the market to treat non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Being plant-based, crofelemer has a very mild/minimal side-effect profile. Crofelemer is also in clinical trials to treat non-infectious diarrhea in oncology patients who are currently on chemotherapy. Conte mentioned that the company is just weeks away from the release of pivotal Phase 3 data in this indication. This would allow for the filing of an sNDA for this indication before year-end or early 2024. Finally, we discussed the commercial market sizes of the HIV/AIDS and oncology/chemotherapy markets. Those interested can listen to the episode on Apple Podcasts, Google Podcasts, Spotify, as well as our website.
Water Tower Research is built on the foundation of democratizing information flow. We bridge the growing information gap between companies and investors through our investor engagement strategies and open-access research platform.
Our research analysts are Wall Street veterans with the experience and knowledge to work with companies and investors in tandem. We provide access to the information and content that anchors the due diligence process for both professional money managers and individual investors. We leverage traditional research distribution channels and the best of modern digital strategies and tactics to amplify this information flow globally to engage all categories of investors and stakeholders.
Information flow is the foundation for creating investor awareness, knowledge, and engagement. Our mission is to help companies and investors have the tools they need and achieve their goals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.